vs
AMN HEALTHCARE SERVICES INC（AMN）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
AMN HEALTHCARE SERVICES INC的季度营收约是Royalty Pharma plc的1.2倍（$748.2M vs $622.0M），Royalty Pharma plc净利率更高（34.4% vs -1.0%，领先35.5%），Royalty Pharma plc同比增速更快（4.8% vs 1.8%），过去两年Royalty Pharma plc的营收复合增速更高（4.6% vs -4.5%）
AMN医疗保健服务公司是美国领先的医疗人力资源解决方案提供商，主要为医院、诊所等各类医疗机构提供护士、医师、医技人员及其他临床、非临床岗位的临时与长期派遣服务，同时提供医护团队管理技术支持及相关咨询服务。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
AMN vs RPRX — 直观对比
营收规模更大
AMN
是对方的1.2倍
$622.0M
营收增速更快
RPRX
高出2.9%
1.8%
净利率更高
RPRX
高出35.5%
-1.0%
两年增速更快
RPRX
近两年复合增速
-4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $748.2M | $622.0M |
| 净利润 | $-7.7M | $214.2M |
| 毛利率 | 26.1% | — |
| 营业利润率 | 1.1% | 62.4% |
| 净利率 | -1.0% | 34.4% |
| 营收同比 | 1.8% | 4.8% |
| 净利润同比 | 95.9% | 2.9% |
| 每股收益（稀释后） | $-0.19 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMNRPRX
| Q4 25 | $748.2M | $622.0M | ||
| Q3 25 | $634.5M | $609.3M | ||
| Q2 25 | $658.2M | $578.7M | ||
| Q1 25 | $689.5M | $568.2M | ||
| Q4 24 | $734.7M | $593.6M | ||
| Q3 24 | $687.5M | $564.7M | ||
| Q2 24 | $740.7M | $537.3M | ||
| Q1 24 | $820.9M | $568.0M |
净利润AMNRPRX
| Q4 25 | $-7.7M | $214.2M | ||
| Q3 25 | $29.3M | $288.2M | ||
| Q2 25 | $-116.2M | $30.2M | ||
| Q1 25 | $-1.1M | $238.3M | ||
| Q4 24 | $-187.5M | $208.2M | ||
| Q3 24 | $7.0M | $544.0M | ||
| Q2 24 | $16.2M | $102.0M | ||
| Q1 24 | $17.3M | $4.8M |
毛利率AMNRPRX
| Q4 25 | 26.1% | — | ||
| Q3 25 | 29.1% | — | ||
| Q2 25 | 29.8% | — | ||
| Q1 25 | 28.7% | — | ||
| Q4 24 | 29.8% | — | ||
| Q3 24 | 31.0% | — | ||
| Q2 24 | 31.0% | — | ||
| Q1 24 | 31.4% | — |
营业利润率AMNRPRX
| Q4 25 | 1.1% | 62.4% | ||
| Q3 25 | 7.5% | 70.1% | ||
| Q2 25 | -18.8% | 36.3% | ||
| Q1 25 | 1.8% | 94.0% | ||
| Q4 24 | -27.6% | 60.9% | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 5.1% | 50.2% | ||
| Q1 24 | 4.9% | -13.0% |
净利率AMNRPRX
| Q4 25 | -1.0% | 34.4% | ||
| Q3 25 | 4.6% | 47.3% | ||
| Q2 25 | -17.7% | 5.2% | ||
| Q1 25 | -0.2% | 41.9% | ||
| Q4 24 | -25.5% | 35.1% | ||
| Q3 24 | 1.0% | 96.3% | ||
| Q2 24 | 2.2% | 19.0% | ||
| Q1 24 | 2.1% | 0.8% |
每股收益（稀释后）AMNRPRX
| Q4 25 | $-0.19 | $0.49 | ||
| Q3 25 | $0.76 | $0.67 | ||
| Q2 25 | $-3.02 | $0.07 | ||
| Q1 25 | $-0.03 | $0.55 | ||
| Q4 24 | $-4.90 | $0.46 | ||
| Q3 24 | $0.18 | $1.21 | ||
| Q2 24 | $0.42 | $0.23 | ||
| Q1 24 | $0.45 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $34.0M | $618.7M |
| 总债务越低越好 | $767.1M | $9.0B |
| 股东权益账面价值 | $642.1M | $9.7B |
| 总资产 | $2.1B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.19× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资AMNRPRX
| Q4 25 | $34.0M | $618.7M | ||
| Q3 25 | $52.6M | $938.9M | ||
| Q2 25 | $41.5M | $631.9M | ||
| Q1 25 | $55.8M | $1.1B | ||
| Q4 24 | $10.6M | $929.0M | ||
| Q3 24 | $30.6M | $950.1M | ||
| Q2 24 | $48.0M | $1.8B | ||
| Q1 24 | $50.6M | $843.0M |
总债务AMNRPRX
| Q4 25 | $767.1M | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $1.1B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
股东权益AMNRPRX
| Q4 25 | $642.1M | $9.7B | ||
| Q3 25 | $644.4M | $9.6B | ||
| Q2 25 | $607.6M | $9.5B | ||
| Q1 25 | $715.1M | $9.8B | ||
| Q4 24 | $706.6M | $10.3B | ||
| Q3 24 | $890.7M | $10.3B | ||
| Q2 24 | $876.9M | $9.8B | ||
| Q1 24 | $854.2M | $9.9B |
总资产AMNRPRX
| Q4 25 | $2.1B | $19.6B | ||
| Q3 25 | $2.1B | $19.3B | ||
| Q2 25 | $2.2B | $18.3B | ||
| Q1 25 | $2.4B | $17.6B | ||
| Q4 24 | $2.4B | $18.2B | ||
| Q3 24 | $2.7B | $18.0B | ||
| Q2 24 | $2.8B | $17.7B | ||
| Q1 24 | $2.9B | $16.1B |
负债/权益比AMNRPRX
| Q4 25 | 1.19× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 1.49× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $75.6M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $67.6M | — |
| 自由现金流率自由现金流/营收 | 9.0% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | — | 3.86× |
| 过去12个月自由现金流最近4个季度 | $233.8M | — |
8季度趋势，按日历期对齐
经营现金流AMNRPRX
| Q4 25 | $75.6M | $827.1M | ||
| Q3 25 | $22.7M | $702.6M | ||
| Q2 25 | $78.5M | $364.0M | ||
| Q1 25 | $92.7M | $596.1M | ||
| Q4 24 | $72.8M | $742.5M | ||
| Q3 24 | $66.7M | $703.6M | ||
| Q2 24 | $99.5M | $658.2M | ||
| Q1 24 | $81.4M | $664.6M |
自由现金流AMNRPRX
| Q4 25 | $67.6M | — | ||
| Q3 25 | $14.8M | — | ||
| Q2 25 | $68.7M | — | ||
| Q1 25 | $82.7M | — | ||
| Q4 24 | $56.6M | — | ||
| Q3 24 | $47.4M | — | ||
| Q2 24 | $72.2M | — | ||
| Q1 24 | $63.2M | — |
自由现金流率AMNRPRX
| Q4 25 | 9.0% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 10.4% | — | ||
| Q1 25 | 12.0% | — | ||
| Q4 24 | 7.7% | — | ||
| Q3 24 | 6.9% | — | ||
| Q2 24 | 9.8% | — | ||
| Q1 24 | 7.7% | — |
资本支出强度AMNRPRX
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.2% | — | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.7% | — | ||
| Q1 24 | 2.2% | — |
现金转化率AMNRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | 0.77× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 9.54× | 1.29× | ||
| Q2 24 | 6.13× | 6.45× | ||
| Q1 24 | 4.70× | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMN
| Travel Nurse Staffing | $208.3M | 28% |
| Allied Staffing | $146.9M | 20% |
| Labor Disruption Services | $124.3M | 17% |
| Technology And Workforce Solutions | $88.0M | 12% |
| Language Services | $69.9M | 9% |
| Other | $29.6M | 4% |
| International Nurse Staffing | $29.6M | 4% |
| Interim Leadership Staffing | $24.1M | 3% |
| Vendor Management Systems | $16.3M | 2% |
| Local Staffing | $8.6M | 1% |
| International Nurse Permanent Placement | $2.6M | 0% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
